- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00714493
RESTART C0168Z05 Rheumatoid Arthritis Study
29 août 2013 mis à jour par: Centocor Ortho Biotech Services, L.L.C.
A Phase 4, Multicenter, Open-Label, Assessor-Blinded Switch Study of the Efficacy and Safety of Infliximab (REMICADE) in Patients With Active Rheumatoid Arthritis Who Are Responding Inadequately to Etanercept (ENBREL) or Adalimumab (HUMIRA).
The purpose of this study is to assess the effectiveness of treatment in patients with active rheumatoid arthritis who are having an inadequate response to at least 3 months of treatment with etanercept or adalimumab in addition to methotrexate.
Aperçu de l'étude
Statut
Complété
Les conditions
Intervention / Traitement
Description détaillée
This is a Phase 4, multi center, open-label, assessor blinded, switch study of infliximab in patients with active rheumatoid arthritis who are receiving methotrexate and are having an inadequate response to their current treatment with etanercept or adalimumab.
The last dose of etanercept must have been at least 1 week but not more than 2 weeks prior to the first infliximab study infusion.
The last dose of adalimumab must have been administered at least 2 weeks but not more than 4 weeks prior to the first infliximab study infusion.
The study will be conducted for 30 weeks and will include 200 patients.
All eligible patients will receive 3 mg/kg infliximab infusions (drug given into a vein) at weeks 0, 2, and 6 and every 8 weeks thereafter, if they achieve a European League Against Rheumatism (EULAR) response on their current dose of infliximab.
Patients who do not achieve a EULAR response will increase their dose from 3mg/kg to 5 mg/kg at week 14.
Patients who do not achieve a EULAR response at week 22 will increase from either 3 mg/kg to 5 mg/kg or from 5mg/kg to 7 mg/kg.
The last study infusion will take place at week 22.
The last study visit for effectiveness evaluations will take place at week 26.
A week 30 follow-up visit will be performed for adverse events and tuberculosis evaluations, health economics assessments, and review of concomitant medications.
All patients who end the study early will be required to complete all assessments.
Patients will receive 3 mg/kg infliximab infusions at weeks 0, 2, and 6.
If patients achieve European League Against Rheumatism (EULAR) response, they will remain on their current dose.
Patients who do not demonstrate a EULAR response will increase their infliximab dose from 3 mg/kg to 5 mg/kg at week 14.
At week 22, patients will also increase their infliximab dose from 3 mg/kg to 5mg/kg or from 5 mg/kg to 7mg/kg if they do not demonstrate a EULAR response.
Type d'étude
Interventionnel
Inscription (Réel)
203
Phase
- Phase 4
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Lieux d'étude
-
-
-
Frankfurt, Allemagne
-
Holdenfelde, Allemagne
-
Leipzig, Allemagne
-
Muenchen, Allemagne
-
München, Allemagne
-
Ratingen, Allemagne
-
-
-
-
-
Hamilton Ontario, Canada
-
-
British Columbia
-
Vancouver, British Columbia, Canada
-
-
Manitoba
-
Winnipeg, Manitoba, Canada
-
-
Newfoundland and Labrador
-
St. John'S, Newfoundland and Labrador, Canada
-
-
Ontario
-
Toronto, Ontario, Canada
-
-
-
-
-
Madrid, Espagne
-
Oviedo, Espagne
-
Santiago De Compostela, Espagne
-
-
-
-
-
Helsinki, Finlande
-
-
-
-
-
Bordeaux Cedex, France
-
Limoges, France
-
Montivilliers, France
-
Orleans, France
-
-
-
-
-
Ashkelon, Israël
-
Beer Yaakov, Israël
-
Haifa, Israël
-
Kfar Saba, Israël
-
Ramat Gan, Israël
-
Rehovot, Israël
-
Tel-Aviv, Israël
-
-
-
-
-
Graz-Eggenberg, L'Autriche
-
Wien, L'Autriche
-
-
-
-
-
Alkmaar, Pays-Bas
-
-
-
-
-
Leeds, Royaume-Uni
-
London, Royaume-Uni
-
Wigan, Royaume-Uni
-
-
-
-
Alabama
-
Huntsville, Alabama, États-Unis
-
-
Arizona
-
Paradise Valley, Arizona, États-Unis
-
Tucson, Arizona, États-Unis
-
-
California
-
Santa Monica, California, États-Unis
-
-
Connecticut
-
Bridgeport, Connecticut, États-Unis
-
-
Delaware
-
Lewes, Delaware, États-Unis
-
-
Florida
-
Boca Raton, Florida, États-Unis
-
Palm Harbor, Florida, États-Unis
-
Tamarac, Florida, États-Unis
-
Vero Beach, Florida, États-Unis
-
-
Georgia
-
Atlanta, Georgia, États-Unis
-
-
Illinois
-
Moline, Illinois, États-Unis
-
Springfield, Illinois, États-Unis
-
-
Kentucky
-
Lexington, Kentucky, États-Unis
-
-
Maryland
-
Wheaton, Maryland, États-Unis
-
-
Michigan
-
Saint Clair Shores, Michigan, États-Unis
-
-
Minnesota
-
Eagan, Minnesota, États-Unis
-
-
Missouri
-
Saint Louis, Missouri, États-Unis
-
Springfield, Missouri, États-Unis
-
-
New Jersey
-
Berkeley Heights, New Jersey, États-Unis
-
Freehold, New Jersey, États-Unis
-
-
New York
-
Albany, New York, États-Unis
-
Syracuse, New York, États-Unis
-
-
North Carolina
-
Chapel Hill, North Carolina, États-Unis
-
-
Ohio
-
Columbus, Ohio, États-Unis
-
Mayfield, Ohio, États-Unis
-
Middleburg Heights, Ohio, États-Unis
-
-
Oklahoma
-
Tulsa, Oklahoma, États-Unis
-
-
Pennsylvania
-
Allentown, Pennsylvania, États-Unis
-
Duncansville, Pennsylvania, États-Unis
-
Wexford, Pennsylvania, États-Unis
-
-
South Carolina
-
Charleston, South Carolina, États-Unis
-
Greenville, South Carolina, États-Unis
-
-
Tennessee
-
Jackson, Tennessee, États-Unis
-
Nashville, Tennessee, États-Unis
-
-
Texas
-
Amarillo, Texas, États-Unis
-
Dallas, Texas, États-Unis
-
Fort Worth, Texas, États-Unis
-
Houston, Texas, États-Unis
-
Mesquite, Texas, États-Unis
-
Temple, Texas, États-Unis
-
Tyler, Texas, États-Unis
-
-
Virginia
-
Burke, Virginia, États-Unis
-
Reston, Virginia, États-Unis
-
-
Washington
-
Seattle, Washington, États-Unis
-
-
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
18 ans et plus (Adulte, Adulte plus âgé)
Accepte les volontaires sains
Non
Sexes éligibles pour l'étude
Tout
La description
Inclusion Criteria:
- Patients must have rheumatoid arthritis
- Patients must have greater than or equal to 6 tender joints and greater than or equal to 6 swollen joints
- Patients must have inadequate disease response to etanercept or adalimumab
- Patients must have received etanercept or adalimumab in combination with methotrexate for a minimum of at least 3 months prior to the screening visit. The last dose of etanercept must have been given at least 1 week but not more than 2 weeks prior to first infliximab infusion. The last dose of adalimumab must have been administered at least 2 weeks but not more than 4 weeks prior to first infliximab infusion.
Exclusion Criteria:
- Patients who have a history of latent or active TB
- Have inflammatory disease other than rheumatoid arthritis
- Have had a chronic or recurrent infectious disease.
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Autre: 001
Infliximab3 mg/kg at week 0,2,6; Increase to 5mg/kg or 7 mg/kg based on EULAR response
|
3 mg/kg at week 0,2,6; Increase to 5mg/kg or 7 mg/kg based on EULAR response
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Percent of Patients Who Achieved a EULAR (The European League Against Rheumatism) Response at Week 10
Délai: Week 10
|
Percent of patients who achieved EULAR response at Week 10.
EULAR response is defined based on the DAS28 score and the EULAR response criteria (Van Gestel et al, 1996 and 1999).
At a given visit, patients with a DAS28 score of ≤ 5.1 are considered EULAR responders if the improvement from baseline in their DAS28 score is greater than 0.6; Or patients with a DAS28 score > 5.1 are considered EULAR responders if the improvement from baseline in their DAS28 score is > 1.2.
|
Week 10
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Percent of Patients Who Acheived EULAR Response at Week 10 and Maintained Through Week 26 Without Infliximab Dose Increase
Délai: Week 26
|
Percent of patients who achieved EULAR response at Week 10 and maintained through Week 26 without infliximab dose increase
|
Week 26
|
|
Percent of Patients Who Achieved EULAR Response at Week 26, Regardless of EULAR Response Status at Weeks 10, 14, and 22, With or Without Dose Increase Prior to Week 26
Délai: Week 26
|
Percent of patients who achieved EULAR response at Week 26, regardless of EULAR response status at Weeks 10, 14, and 22, with or without dose increase prior to Week 26
|
Week 26
|
|
Change From Baseline in Physical Function (HAQ)
Délai: Week 10
|
Change from baseline in physical function (HAQ) at Week 10.
HAQ assesses the degree of difficulty a person has in accomplishing tasks.
A lower HAQ score indicates less difficulty.
Change from baseline is computed as Week 10 value minus baseline value.
A negative value in change from baseline indicates an improvement.
|
Week 10
|
|
Change From Baseline in Physical Function (HAQ)
Délai: Week 26
|
Change from baseline in physical function (HAQ) at Week 26.
HAQ assesses the degree of difficulty a person has in accomplishing tasks.
A lower HAQ score indicates less difficulty.
Change from baseline is computed as Week 26 value minus baseline value.
A negative value in change from baseline indicates an improvement.
|
Week 26
|
|
Percent of Patients Who Achieved ACR20 at Week 10
Délai: Week 10
|
Percent of patients who achieved ACR20 at Week 10.
A patient is considered achieving ACR20 if the following two conditions are met: 1) An improvement of ≥ 20% from baseline in both the swollen joint count (66 joints) and tender joint count (68 joints; 2) An improvement of ≥ 20% from baseline in at least 3 of the following 5 assessments:Patient's assessment of pain visual analog scale (VAS), Patient's global assessment of disease activity (VAS), Evaluator's global assessment of disease activity (VAS), Patient's assessment of physical function as measured by the HAQ disability index, and CRP.
|
Week 10
|
|
Percent of Patients Who Achieved ACR20 at Weeks 26.
Délai: Week 26
|
Percent of patients who achieved ACR20 at Weeks 26.
A patient is considered achieving ACR20 if the following two conditions are met: 1) An improvement of ≥ 20% from baseline in both the swollen joint count (66 joints) and tender joint count (68 joints; 2) An improvement of ≥ 20% from baseline in at least 3 of the following 5 assessments:Patient's assessment of pain visual analog scale (VAS), Patient's global assessment of disease activity (VAS), Evaluator's global assessment of disease activity (VAS), Patient's assessment of physical function as measured by the HAQ disability index, and CRP.
|
Week 26
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Parrainer
Collaborateurs
Publications et liens utiles
La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude
1 juillet 2008
Achèvement primaire (Réel)
1 janvier 2010
Achèvement de l'étude (Réel)
1 juin 2010
Dates d'inscription aux études
Première soumission
10 juillet 2008
Première soumission répondant aux critères de contrôle qualité
11 juillet 2008
Première publication (Estimation)
14 juillet 2008
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
12 septembre 2013
Dernière mise à jour soumise répondant aux critères de contrôle qualité
29 août 2013
Dernière vérification
1 août 2013
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- CR013879
- C0168Z05 (Autre identifiant: Centocor Ortho Biotech Services, L.L.C.)
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .